Alimera Sciences Stock Forecast, Price & News

+0.03 (+0.33 %)
(As of 06/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume13,921 shs
Average Volume65,383 shs
Market Capitalization$62.59 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ALIM News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

Alimera Sciences logo

About Alimera Sciences

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.20 out of 5 stars

Medical Sector

971st out of 2,105 stocks

Pharmaceutical Preparations Industry

474th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions

Is Alimera Sciences a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alimera Sciences stock.
View analyst ratings for Alimera Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Alimera Sciences?

Wall Street analysts have given Alimera Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alimera Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Alimera Sciences' next earnings date?

Alimera Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Alimera Sciences

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) announced its quarterly earnings data on Tuesday, April, 27th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.09. The biopharmaceutical company had revenue of $11.21 million for the quarter, compared to the consensus estimate of $11.60 million.
View Alimera Sciences' earnings history

How has Alimera Sciences' stock price been impacted by Coronavirus (COVID-19)?

Alimera Sciences' stock was trading at $5.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALIM stock has increased by 72.7% and is now trading at $9.05.
View which stocks have been most impacted by COVID-19

When did Alimera Sciences' stock split? How did Alimera Sciences' stock split work?

Shares of Alimera Sciences reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for ALIM?

2 analysts have issued 1-year price targets for Alimera Sciences' shares. Their forecasts range from $16.00 to $16.50. On average, they anticipate Alimera Sciences' stock price to reach $16.25 in the next year. This suggests a possible upside of 79.6% from the stock's current price.
View analysts' price targets for Alimera Sciences
or view top-rated stocks among Wall Street analysts.

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the following people:
  • Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 67, Pay $205k)
  • Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 53, Pay $630.37k)
  • Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 57, Pay $429.36k)
  • Dr. Philip Ashman, COO & Sr. VP of Commercial Operations - Europe (Age 56, Pay $417.14k)
  • Mr. J. Philip Jones, Chief Financial Officer (Age 57)
  • Christopher S. Visick, VP, Gen. Counsel & Sec.
  • Dr. David Dyer, Chief Retina Specialist

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences CEO Rick Eiswirth on Rick Eiswirth has an approval rating of 100% among Alimera Sciences' employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Alimera Sciences' key competitors?

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (6.15%), Renaissance Technologies LLC (2.10%), Knott David M (0.84%), Cooper Creek Partners Management LLC (0.55%), Diametric Capital LP (0.38%) and Geode Capital Management LLC (0.32%). Company insiders that own Alimera Sciences stock include James R Largent, John Philip Jones, John Snisarenko, Philip Ashman and Richard S Eiswirth Jr.
View institutional ownership trends for Alimera Sciences

Which institutional investors are selling Alimera Sciences stock?

ALIM stock was sold by a variety of institutional investors in the last quarter, including Knott David M, and Renaissance Technologies LLC.
View insider buying and selling activity for Alimera Sciences
or view top insider-selling stocks.

Which institutional investors are buying Alimera Sciences stock?

ALIM stock was purchased by a variety of institutional investors in the last quarter, including Cooper Creek Partners Management LLC, Diametric Capital LP, Perritt Capital Management Inc., PDT Partners LLC, Citadel Advisors LLC, Citadel Advisors LLC, Geode Capital Management LLC, and Acadian Asset Management LLC. Company insiders that have bought Alimera Sciences stock in the last two years include James R Largent, John Philip Jones, John Snisarenko, and Richard S Eiswirth Jr.
View insider buying and selling activity for Alimera Sciences
or or view top insider-buying stocks.

How do I buy shares of Alimera Sciences?

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $9.05.

How much money does Alimera Sciences make?

Alimera Sciences has a market capitalization of $62.59 million and generates $50.82 million in revenue each year. The biopharmaceutical company earns $-5,340,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does Alimera Sciences have?

Alimera Sciences employs 130 workers across the globe.

What is Alimera Sciences' official website?

The official website for Alimera Sciences is

Where are Alimera Sciences' headquarters?

Alimera Sciences is headquartered at 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]

This page was last updated on 6/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.